drugset
drugset / Trial / NCT06846489

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

NCT06846489 ↗

Phase 2 Recruiting 50 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma

Timeline

Start
2025-04-14
Primary completion
2033-02-10
Completion
2033-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

mantle cell lymphoma